124
Views
0
CrossRef citations to date
0
Altmetric
Review

Proteolytic signaling in cancer

, &
Pages 345-355 | Received 16 Aug 2023, Accepted 17 Oct 2023, Published online: 27 Oct 2023
 

ABSTRACT

Introduction

Cancer is a disease of (altered) biological pathways, often driven by somatic mutations and with several implications. Therefore, the identification of potential markers of disease is challenging. Given the large amount of biological data generated with omics approaches, oncology has experienced significant contributions. Proteomics mapping of protein fragments, derived from proteolytic processing events during oncogenesis, may shed light on (i) the role of active proteases and (ii) the functional implications of processed substrates in biological signaling circuits. Both outcomes have the potential for predicting diagnosis/prognosis in diseases like cancer. Therefore, understanding proteolytic processing events and their downstream implications may contribute to advances in the understanding of tumor biology and targeted therapies in precision medicine.

Areas covered

Proteolytic events associated with some hallmarks of cancer (cell migration and proliferation, angiogenesis, metastasis, as well as extracellular matrix degradation) will be discussed. Moreover, biomarker discovery and the use of proteomics approaches to uncover proteolytic signaling events will also be covered.

Expert opinion

Proteolytic processing is an irreversible protein post-translational modification and the deconvolution of biological data resulting from the study of proteolytic signaling events may be used in both patient diagnosis/prognosis and targeted therapies in cancer.

Article highlights

  • Proteolytic processing is an irreversible protein post-translational modification; that affects the fate of processed proteins.

  • Proteolytic signaling is nearly ubiquitously present among the hallmarks of cancer.

  • Targeting (proteolytically processed) protein fragments may help in the detection/prognostics of cancer, contributing to improving personalized medicine.

Declaration of interest

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

Murilo Salardani and Uilla Barcick have contributed equally to this work. André Zelanis wrote and revised the manuscript.

Acknowledgments

The authors thank Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; grants # 2022/15421-0 and 2021/05087-3) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Additional information

Funding

This paper was funded by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; grants # 2022/15421-0 and 2021/05087-3) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.